Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 325 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Liver Function Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function

NCT02521376
View directory record Official record
Conditions
Oncology
Interventions
Entospletinib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Sep 2, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants

NCT00819468
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Teduglutide
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Sep 2, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2216684 in Participants With Impaired Hepatic Function

NCT01241435
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
LY2216684
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2018 · Synced Sep 2, 2026, 5:21 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Mitochondrial Function in Patients With Severe Liver Disease

NCT02457702
View directory record Official record
Conditions
Hepatic Insufficiency, Hypoalbuminemia
Interventions
Orally administered labeled glycerol
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 2, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects

NCT03369002
View directory record Official record
Conditions
Hepatic Impairment
Interventions
seladelpar
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Sep 2, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

NCT02474537
View directory record Official record
Conditions
Hepatic Impairment
Interventions
INC280
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Sep 2, 2026, 5:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Interaction Between Cannabidiol, Meal Ingestion, and Liver Function

NCT04971837
View directory record Official record
Conditions
Metabolism, Liver Function, Pharmacokinetics
Interventions
Cannabidiol (CBD) powder formulation, Cannabidiol (CBD) Oil based tincture formulation, Cannabidiol (CBD) Gum Arabic, maltodextrin base formulation, Cannabidiol (CBD) Gum Arabic, sorbitol base formulation, Cannabidiol (CBD) Isolate in water formulation, CBD matching Placebo
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 2, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function

NCT04469920
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Sep 2, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function

NCT02296905
View directory record Official record
Conditions
Hepatic Impairment
Interventions
ABT-493, ABT-530
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Sep 2, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems

NCT06957756
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
BI 1584862
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Chandler, Arizona • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 2, 2026, 5:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function

NCT03902366
View directory record Official record
Conditions
Hepatitis C, Alcohol Use Disorder
Interventions
Neuropsychological assessment, Neuroimaging
Diagnostic Test · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Sep 2, 2026, 5:21 AM EDT
Terminated Phase 1 Interventional

Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function

NCT02626312
View directory record Official record
Conditions
Cholangiocarcinoma, Cirrhosis, Hepatocellular Carcinoma, Metastatic Malignant Neoplasm in the Liver
Interventions
Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Radiation Therapy, Survey Administration
Other · Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 2, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function

NCT06048302
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
Obicetrapib
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Saint Paul, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 2, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

A Study of Siliphos in Adults With Non-alcoholic Steatohepatitis (NASH)

NCT00443079
View directory record Official record
Conditions
Fatty Liver
Interventions
IdB 1016 (Siliphos), Matched placebo
Drug
Lead sponsor
Heather Patton
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 2, 2026, 5:21 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Trial to Examine if Repinatrabit is Processed Differently in Adults With Reduced Liver or Kidney Function Compared to Adults With Normal Liver and Kidney Function

NCT07713758
View directory record Official record
Conditions
Phenylketonuria
Interventions
Repinatrabit
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 2, 2026, 5:21 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Effect of Sugar Sweetened and Diet Beverages Consumed as Part of a Weight-Maintenance Diet on Fat Storage

NCT02252952
View directory record Official record
Conditions
Focus: Understanding the Obesogenic Potential of Sugars and Non-caloric Sweeteners
Interventions
Beverage Consumption
Other
Lead sponsor
Rippe Lifestyle Institute
Industry
Eligibility
20 Years to 50 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Celebration, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2014 · Synced Sep 2, 2026, 5:21 AM EDT
Enrolling by invitation No phase listed Observational

Physiologic and Functional Adaptations of Insulin Sensitive Tissues

NCT03407833
View directory record Official record
Conditions
Diabetes, Insulin Resistance, Obesity, Bariatric Surgery Candidate, Roux-en-y Gastric Bypass, Liver Diseases
Interventions
Endoscopy biopsy, Surgical biopsy, Mixed-meal tolerance test, Excised Liver Tissue Sampling
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 2, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

NCT05624710
View directory record Official record
Conditions
Renal Insufficiency, Kidney Diseases
Interventions
INCB054707
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Tustin, California • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 2, 2026, 5:21 AM EDT
Completed No phase listed Observational

Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD)

NCT01419158
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency, Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
Alpha-1 Foundation
Other
Eligibility
18 Years and older
Enrollment
3,457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
18
States / cities
Los Angeles, California • Denver, Colorado • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Sep 2, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function

NCT05283915
View directory record Official record
Conditions
Hepatic Function Abnormal
Interventions
tolebrutinib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 2, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects

NCT02857868
View directory record Official record
Conditions
Hepatic Impairment
Interventions
ABL001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 2, 2026, 5:21 AM EDT
Not listed No phase listed Observational

ALT Routinely Recorded Remotely: A Comparator Study of Liver Function Tests Using the Tasso+ to Venipuncture.

NCT05259618
View directory record Official record
Conditions
Elevated Alanine Transaminase (ALT)
Interventions
Tasso+ SST
Other
Lead sponsor
Tasso Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Aurora, Colorado • New York, New York • Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Sep 2, 2026, 5:21 AM EDT
Recruiting Not applicable Interventional

Microbiome Modulation With Prebiotics in PTSD and Cirrhosis

NCT06464952
View directory record Official record
Conditions
Cirrhosis, PTSD
Interventions
Resistant potato starch, Powdered cellulose
Dietary Supplement
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 2, 2026, 5:21 AM EDT
Completed Phase 4 Interventional

A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions

NCT00144248
View directory record Official record
Conditions
HIV Infections, Hepatic Insufficiency
Interventions
nevirapine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
5
States / cities
Bakersfield, California • San Francisco, California • Albany, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 2, 2026, 5:21 AM EDT